Literature DB >> 20921512

What predicts mortality in Parkinson disease?: a prospective population-based long-term study.

E B Forsaa1, J P Larsen, T Wentzel-Larsen, G Alves.   

Abstract

OBJECTIVE: To identify independent risk factors of mortality in a community-based Parkinson disease (PD) cohort during prospective long-term follow-up.
METHODS: A community-based prevalent sample of 230 patients with PD from southwestern Norway was followed prospectively with repetitive assessments of motor and nonmotor symptoms from 1993 to 2005. Information on vital status until October 20, 2009, was obtained from the National Population Register in Norway. Cox proportional hazards models were applied to identify independent predictors of mortality during follow-up. Chronological age, Unified Parkinson's Disease Rating Scale (UPDRS) motor score, levodopa equivalent dose, probable REM sleep behavior disorder, psychotic symptoms, dementia, and use of antipsychotics were included as time-dependent variables, and age at onset (AAO) and sex as time-independent variables.
RESULTS: Of 230 patients, 211 (92%) died during the study period. Median survival time from motor onset was 15.8 years (range 2.2-36.6). Independent predictors of mortality during follow-up were AAO (hazard ratio [HR] 1.40 for 10-years increase, p = 0.029), chronological age (HR 1.51 for 10-years increase, p = 0.043), male sex (HR 1.63, p = 0.001), UPDRS motor score (HR 1.18 for 10-point increase, p < 0.001), psychotic symptoms (HR 1.45, p = 0.039), and dementia (HR 1.89, p = 0.001).
CONCLUSIONS: This population-based long-term study demonstrates that in addition to AAO, chronological age, motor severity, and dementia, psychotic symptoms independently predict increased mortality in PD. In contrast, no significant impact of antipsychotic or antiparkinsonian drugs on survival was observed in our PD cohort. Early prevention of motor progression and development of psychosis and dementia may be the most promising strategies to increase life expectancy in PD.

Entities:  

Mesh:

Year:  2010        PMID: 20921512     DOI: 10.1212/WNL.0b013e3181f61311

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  78 in total

Review 1.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

2.  Estimation of Parkinson's disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach.

Authors:  O Chillag-Talmor; N Giladi; S Linn; T Gurevich; B El-Ad; B Silverman; N Friedman; C Peretz
Journal:  J Neurol       Date:  2012-07-07       Impact factor: 4.849

3.  Co-occurrence of parkinsonism and dementia in clinical practice: relevant differential diagnoses.

Authors:  I Liepelt-Scarfone; M Jamour; W Maetzler
Journal:  Z Gerontol Geriatr       Date:  2012-01       Impact factor: 1.281

Review 4.  The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases.

Authors:  Jenny Lam; Nichole Coleman; April Lourdes A Garing; Heike Wulff
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

5.  Dementia in long-term Parkinson's disease patients: a multicentre retrospective study.

Authors:  Jennifer Y Y Szeto; Courtney C Walton; Alexandra Rizos; Pablo Martinez-Martin; Glenda M Halliday; Sharon L Naismith; K Ray Chaudhuri; Simon J G Lewis
Journal:  NPJ Parkinsons Dis       Date:  2020-01-07

6.  Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinson's disease.

Authors:  Seok Jong Chung; Han Soo Yoo; Hye Sun Lee; Yang Hyun Lee; KyoungWon Baik; Jin Ho Jung; Byoung Seok Ye; Young H Sohn; Phil Hyu Lee
Journal:  J Neurol       Date:  2021-05-04       Impact factor: 4.849

Review 7.  Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists.

Authors:  Daniel Martinez-Ramirez; Michael S Okun; Michael S Jaffee
Journal:  Neurodegener Dis Manag       Date:  2016-07-13

8.  Affective Correlates of Psychosis in Parkinson's Disease.

Authors:  Stewart A Factor; Michael K Scullin; Alan Freeman; Donald L Bliwise; William M McDonald; Felicia C Goldstein
Journal:  Mov Disord Clin Pract       Date:  2016-06-16

9.  Optogenetic Stimulation of Frontal D1 Neurons Compensates for Impaired Temporal Control of Action in Dopamine-Depleted Mice.

Authors:  Young-Cho Kim; Sang-Woo Han; Stephanie L Alberico; Rafael N Ruggiero; Benjamin De Corte; Kuan-Hua Chen; Nandakumar S Narayanan
Journal:  Curr Biol       Date:  2016-12-15       Impact factor: 10.834

10.  The Vulnerable Ventral Tegmental Area in Parkinson's Disease.

Authors:  Stephanie L Alberico; Martin D Cassell; Nandakumar S Narayanan
Journal:  Basal Ganglia       Date:  2015-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.